BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15368546)

  • 21. Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome.
    Meyr F; Escherich G; Mann G; Klingebiel T; Kulozik A; Rossig C; Schrappe M; Henze G; von Stackelberg A; Hitzler J
    Br J Haematol; 2013 Jul; 162(1):98-106. PubMed ID: 23594030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study.
    Whitlock JA; Sather HN; Gaynon P; Robison LL; Wells RJ; Trigg M; Heerema NA; Bhatia S
    Blood; 2005 Dec; 106(13):4043-9. PubMed ID: 16109782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic effectiveness of the ALL-XH-99 protocol for childhood acute lymphoblastic leukemia.
    Wang YR; Jin RM; Xu JW; Xiao Y; Zhou DF; Zhang ZQ
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb; 10(1):1-4. PubMed ID: 18289459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Equal frequency of TEL/AML1 rearrangements in children with acute lymphoblastic leukemia with and without Down syndrome.
    Steiner M; Attarbaschi A; König M; Nebral K; Gadner H; Haas OA; Mann G;
    Pediatr Hematol Oncol; 2005; 22(3):229-34. PubMed ID: 16020107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
    Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
    J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
    Creutzig U; Büchner T; Sauerland MC; Zimmermann M; Reinhardt D; Döhner H; Schlenk RF
    Cancer; 2008 Feb; 112(3):562-71. PubMed ID: 18076087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
    Rivera GK; Zhou Y; Hancock ML; Gajjar A; Rubnitz J; Ribeiro RC; Sandlund JT; Hudson M; Relling M; Evans WE; Pui CH
    Cancer; 2005 Jan; 103(2):368-76. PubMed ID: 15599932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vincristine pharmacokinetics in children with Down syndrome.
    Lönnerholm G; Frost BM; Söderhäll S; de Graaf SS
    Pediatr Blood Cancer; 2009 Jan; 52(1):123-5. PubMed ID: 18615507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of Down's syndrome on management and outcome of patients with congenital intrinsic duodenal obstruction.
    Niramis R; Anuntkosol M; Tongsin A; Mahatharadol V
    J Pediatr Surg; 2010 Jul; 45(7):1467-72. PubMed ID: 20638526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute lymphoblastic leukemia in adolescents and young adults in Finland.
    Usvasalo A; Räty R; Knuutila S; Vettenranta K; Harila-Saari A; Jantunen E; Kauppila M; Koistinen P; Parto K; Riikonen P; Salmi TT; Silvennoinen R; Elonen E; Saarinen-Pihkala UM
    Haematologica; 2008 Aug; 93(8):1161-8. PubMed ID: 18556413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical characteristics and treatment outcome of children with acute lymphocytic leukemia and Down's syndrome. A Pediatric Oncology Group study.
    Ragab AH; Abdel-Mageed A; Shuster JJ; Frankel LS; Pullen J; van Eys J; Sullivan MP; Boyett J; Borowitz M; Crist WM
    Cancer; 1991 Feb; 67(4):1057-63. PubMed ID: 1825025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Down syndrome, drug metabolism and chromosome 21.
    Taub JW; Ge Y
    Pediatr Blood Cancer; 2005 Jan; 44(1):33-9. PubMed ID: 15390307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment results in children with the standard risk acute lymphoblastic leukemia treated with high dose of methotrexate (5.0 g/m2). 11 years of the Polish Pediatric Leukemia/Lymphoma Study Group experience].
    Derwich K; Wachowiaki J; Kaczmarek-Kanoldi M; Balcerska A; Balwierz W; Chybicka A; Kowalczyk JR; Matysiak M; Jackowska T; Sońta-Jakimczyk D; Wysocki M; Chełmecka-Hanuszewicz L; Cwiklińska M; Kołtan A; Malinowska I; Odój T; Płoszyńska A; Steczowicz M; Wojciechowska V; Wójtowicz A;
    Przegl Lek; 2006; 63(1):7-10. PubMed ID: 16892891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overt testicular disease (OTD) at diagnosis is not associated with a poor prognosis in childhood acute lymphoblastic leukemia: results of the EORTC CLG Study 58881.
    Sirvent N; Suciu S; Bertrand Y; Uyttebroeck A; Lescoeur B; Otten J
    Pediatr Blood Cancer; 2007 Sep; 49(3):344-8. PubMed ID: 16358303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.
    Schrauder A; Reiter A; Gadner H; Niethammer D; Klingebiel T; Kremens B; Peters C; Ebell W; Zimmermann M; Niggli F; Ludwig WD; Riehm H; Welte K; Schrappe M
    J Clin Oncol; 2006 Dec; 24(36):5742-9. PubMed ID: 17179108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
    Tolar J; Bostrom BC; La MK; Sather HN
    Pediatr Blood Cancer; 2005 Jul; 45(1):5-9. PubMed ID: 15481062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
    Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
    J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
    Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
    Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
    Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
    J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.